

**AMENDMENT**

**In the Specification :**

Please amend the paragraph beginning at page 4, line 16 as follows:

In preferred embodiments of the invention, the immunogenic composition comprises a second carrier, preferably, aluminum hydroxide (alum) or MF59. Alum can be obtained from Superfos, Bedbaek, Denmark, and is a 3% solution. When present, about 1 mg to about 1.67 mg of alum is used per dose. MF59 is a micro-fluidized emulsion of squalene in water that has been shown to be safe and to augment serum antibody responses to a variety of investigational vaccines. MF59 comprises about 5% squalene, 0.5% Tween TWEEN 80 and about 0.5% Span SPAN 85. The adjuvant MF59 is described in PCT publication No. WO 90/14837, incorporated herein by reference in its entirety. MF59 can be made according to the procedures described in, for example, Ott *et al.*, *Vaccine Design: The Subunit And Adjuvant Approach, 1995*, M.F. Powell and M.J. Newman, Eds., Plenum Press, New York, p. 277-296; Singh *et al.*, *Vaccine, 1998* 16, 1822-1827; Ott *et al.*, *Vaccine, 1995*, 13, 1557-1562; and Valensi *et al.*, *J. Immunol.*, 1994, 153, 4029-39, the disclosures of which are incorporated herein by reference in their entirety.